Tigatuzumab
Tigatuzumab
Tigatuzumab (pronounced tee-ga-too-zoo-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a type of immunotherapy that targets the death receptor 5 (DR5) on the surface of cancer cells.
Etymology
The name "Tigatuzumab" is derived from the scientific nomenclature for therapeutic antibodies, where "-tuzumab" indicates a humanized antibody. The prefix "Tiga-" is likely a proprietary designation by the drug's developer.
Mechanism of Action
Tigatuzumab works by binding to the DR5 receptor on cancer cells, which triggers a process called apoptosis, or programmed cell death. This is a natural process that the body uses to remove old or damaged cells, but in the case of cancer, this process is often disrupted. By triggering apoptosis, Tigatuzumab can help to control the growth and spread of cancer cells.
Clinical Trials
Tigatuzumab has been studied in several clinical trials for its potential use in treating various types of cancer, including colorectal cancer, non-small cell lung cancer, and breast cancer. However, as of now, it has not been approved by the Food and Drug Administration (FDA) for use in the United States.
Related Terms
- Monoclonal antibody
- Immunotherapy
- Apoptosis
- Clinical trial
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Food and Drug Administration
External links
- Medical encyclopedia article on Tigatuzumab
- Wikipedia's article - Tigatuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski